Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0PXYTA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
MEDI-4276
|
|||||
| Synonyms |
MEDI4276; MEDI 4276
Click to Show/Hide
|
|||||
| Organization |
MedImmune LLC; AstraZeneca PLC
|
|||||
| Drug Status |
Terminated in phase 1
|
|||||
| Indication |
In total 2 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Terminated in phase 1
Gastric cancer [ICD11:2B72]
Terminated in phase 1
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
MEDI-4276
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2 ECD2); Receptor tyrosine-protein kinase erbB-2 (HER2 ECD4)
|
Antigen Info | ||||
| Payload Name |
AZ13599185
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Maleimido-caproyl based linker
|
Linker Info | ||||
| Conjugate Type |
Site-specific conjugation through the engineered cysteine (THIOMAB, HC-Cys 239 and 442).
|
|||||
| Puchem SID | ||||||
| ChEBI ID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.